DEXLEVO Is Challenging the World with the First Ever Liquid Polymer Fillers
Korea is expected to enter the super-aging era at the fastest rate globally, and a wide range of its consumers in the market are expected to be comprised of its elderly population. As the economically competent senior generation is attracting attention due to its buying power, various anti-aging products are being introduced into the beauty market. According to Hebronstar, which specializes in management consulting, the domestic anti-aging market is expected to grow at an average annual rate of 13.2%, with cosmetics leading 75% of this growth, followed by the medical sector (18%) and service sector (7%).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220210006093/en/
The 1st Fully Liquid type PCL Injectable for Fundamental Skin Anti-Aging care. (Graphic: Business Wire)
Given the transition of the senior generation into a new major consumer class, the skin beauty market is trending toward minimally invasive and non-invasive procedures that can cover aging beyond beauty. Botulinum toxin and hyaluronic acid filler are the anti-aging procedures that currently lead the market. However, these products have clear limitations in terms of their lasting effectiveness. In addition, owing to the intensified competition due to the market’s low entry barriers, consumers’ ability to discern the quality of various products remains limited.
DEXLEVO is a venture company that has attracted significant interest due to its development of innovative products, such as the world's first successful liquid polymer fillers. The company emerged with a pre-investment valuation of KRW 250 billion during the pre-IPO funding process in November of last year.
Goal to enter the global skincare market
Founded in 2013, DEXLEVO develops beauty products based on biodegradable polymer technology. After significant research, the company developed the world’s first liquid polymer fillers. DEXLEVO’s liquid polymer filler is in a liquid form when outside the body, unlike existing small particle formulations. However, when injected into the body, it transforms into particles and regenerates collagen in the skin to express anti-aging effects. Jaewon You—the CEO of DEXLEVO—said, “While we were looking for an item after setting our business direction in the skincare field, we paid attention to the fact that biodegradable polymer filler products, which were popular in Korea at the time, are in small particle form and are only used in limited areas such as the nasolabial folds.” He added, “By liquefying it, we have developed the world’s first liquid polymer filler without restrictions on use and side effects.”
DEXLEVO’s liquid polymer filler is different from existing fillers in that it promotes collagen regeneration within the skin. Existing fillers also have a collagen regeneration effect. However, since they are in the form of particles, it is impossible to inject them into the skin evenly. Thus, these fillers could only be used for topical areas such as nasolabial folds. However, DEXLEVO solved this limitation. When a high molecular compound is injected into the skin in liquid form, it can be used in various areas by regenerating collagen around the skin while transforming it into small particles within the skin.
Based on differentiated technology, DEXLEVO secured a European CE marking for the liquid polymer filler under the brand name 'GOURI' in the first half of 2021, thereby laying the foundation for its entry into the global market. In addition, upon launching 'GOURI' at AMWC, DEXLEVO signed supply contracts with local companies in Spain, Saudi Arabia, UAE, Europe, Southwest Asia, and Latin America. Jaewon You stated, “With GOURI, which has received European CE (a conformity mark of EC directives) certification since 2022, we are entering into local markets in Europe, the Middle East, and Latin America. In Korea, the product approval process will be completed by 2022 and the product will be released in 2023, following which clinical trials with the US FDA will proceed.”
Secured an investment value of KRW 250 billion
Jaewon You, who gained practical experience at Samyang Corporation and CELLTRION, observed great potential in the skincare market given the rapid restructuring of society into an aging one. Jaewon You stated, “In the pharmaceutical and biofields such as anticancer drugs and drugs for treating rare diseases, it is not easy to compete with global Big Pharma in terms of financial power and research ability, but I believed that we had sufficient competitiveness in the skincare field globally.” He added, “Korea has a high interest in cosmetic procedures due to its culture that values extroversion, and I viewed this as an opportunity to utilize our excellent medical personnel and manufacturing base.”
With the successful launch of 'GOURI' in 2021, DEXLEVO, which participated as the main sponsor of AMWC and signed a supply contract worth about 30 million dollars, raised KRW 26 billion in pre-IPO funding last November. Existing shareholders, which included MAGNA investment and HANA financial investment (KRW 10 billion), Smilegate Investment (Smilegate Aphrodite Serve One Fund; KRW 10 billion), Hyundai Venture Investment (Hyundai Youth Fund No. 2; KRW 4 billion), and Shinhan Capital (KRW 2 billion), participated in the pre-IPO funding.
Interestingly, the investment value was set at 250 billion won, which is approximately six times higher than the pre-investment standard (series B of KRW 40 billion in 2018). Jaewon You stated, “The original funding was planned to be KRW 20 billion, but it was increased to KRW 26 billion due to active investment requests from existing shareholders who highly evaluated the company’s future growth potential.” He added, “In addition to existing shareholders, many venture capitalists and private equity (PE) firms also expressed their intention to invest, but the existing shareholders alone exceeded the planned investment, so the external investment was excluded.”
Additionally, Jaewon You stated, "The future of DEXLEVO is important, and I believe that an IPO is not the goal, but that the IPO will follow. The ultimate goal is to become the number one company in the global beauty industry.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220210006093/en/
Contact information
DEXLEVO
Marketing Department
Chris Jeong
chrisjeong@dexlevo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline4.9.2025 08:00:00 EEST | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round. The round was led by French pharmaceutical group Biocodex and included strong participation from German-based ATHOS, as well as new investor BNP Paribas Fortis Private Equity and existing investors SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II and VIB. Validation of Leadership Position in Microbiome-Based Therapeutics Proceeds will enable MRM Health to complete a Phase 2b clinical trial for its lead program MH002 in patients suffering from mild-to-moderate ulcerative colitis. MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD), with positive clinical da
Abbove Unveils “Mia”: Opening a New Chapter in Digital Wealth Planning in Europe4.9.2025 07:00:00 EEST | Press release
Abbove, the European platform for collaborative and family-centered wealth planning, announces today the launch of Mia, its new artificial intelligence agent. Used by more than 1,100 advisors and deployed to over 37,000 families across Europe, Abbove takes a major step forward in its mission to reimagine the wealth advisory experience in the digital age. Designed to enhance the capabilities of wealth advisors, family officers, and financial experts, Mia acts as an intelligent co-pilot. It simplifies the reading and analysis of complex estate documents, automatically extracts key information, and assists users in the understanding, enrichment, and structuring of wealth data. “The launch of Mia opens an entirely new functional AI vertical on our platform, unlocking near-infinite possibilities for future development. It’s a key milestone that brings us closer to our ambition of becoming the leading pan-European wealth planning platform.” — Guillaume Desclée, Founder & CEO of Abbove Native
Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions4.9.2025 03:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies and Merck KGaA, Darmstadt, Germany, a leading science and technology company, have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated lipid nanoparticle (LNP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903434045/en/ Under the terms of the agreement, Biocytogen will provide proprietary, fully human antibodies derived from its RenMice® platform for evaluation in Merck KGaA, Darmstadt, Germany’s antibody-conjugated LNP services. Merck KGaA, Darmstadt, Germany has been granted an exclusive option to acquire rights to selected antibody assets in return for fees and royalties on sales and su
OpZira, Inc. Launches to Advance Ophthalmic Diagnostics with Innovative Medical Device Portfolio3.9.2025 20:23:00 EEST | Press release
OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced its official formation. OpZira is dedicated to delivering innovative technologies that enhance the detection and monitoring of ocular disease, empowering clinicians with advanced diagnostic tools. OpZira’s creation follows Alcon’s acquisition of LumiThera (https://www.alcon.com/media-release/alcon-completes-acquisition-lumithera/) and its innovative Valeda® Light Delivery System, the first and only FDA-authorized treatment for dry age-related macular degeneration (AMD). As part of the transaction, LumiThera’s diagnostic product lines were spun off to LumiThera shareholders, leading to the establishment of OpZira, Inc. OpZira’s product portfolio includes: AdaptDx Pro® – A wearable dark adaptometer that leverages AI to ensure a consistent patient experience. Impaired dark adaptation speed, a key early indicator of rod-mediated dysfunction, is often among the fir
BTG Bioliquids and NanosTech Partner to Deliver End-to-End Advanced Biofuels Solution3.9.2025 19:19:00 EEST | Press release
BTG Bioliquids BV (BTL), a Netherlands-based leader in fast pyrolysis technology, and NanosTech Technology & Innovations Ltd. (NanosTech), a Canada-based catalyst development and manufacturing company, have signed a Memorandum of Understanding (MOU) to deliver a fully integrated solution to produce advanced, drop-in biofuels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903698730/en/ The partnership combines BTL’s proven fast pyrolysis technology, which converts sustainable biomass into bio-oil, with NanosTech’s proprietary Aquaprocessing (AQP) platform, which upgrades even the most challenging bio-oils into refinery-ready feedstocks to produce fuels such as sustainable aviation fuel (SAF), renewable diesel, and marine fuels. The two companies are now actively collaborating to determine the location in Canada and Europe for the new 500-barrel-per-day modular biorefinery system. This system can be deployed near the feeds
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom